[Survivin supressant: a promising target for cancer therapy and pharmacological profiles of YM155].
Kita
Aya
A
aya.kita@jp.astellas.com
Nakahara
Takahito
T
Takeuchi
Masahiro
M
Kinoyama
Isao
I
Yamanaka
Kentaro
K
Minematsu
Tsuyoshi
T
Mitsuoka
Keisuke
K
Fushiki
Hiroshi
H
Miyoshi
Sousuke
S
Sasamata
Masao
M
Miyata
Keiji
K
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015195:Drug Design; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D051034:Inhibitor of Apoptosis Proteins; D051379:Mice; D008869:Microtubule-Associated Proteins / Q000037:antagonists & inhibitors*; D009285:Naphthoquinones / Q000627:therapeutic use*; D000077022:Survivin; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; C107489:BIRC5 protein, human; D007093:Imidazoles; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009285:Naphthoquinones; D000077022:Survivin; C523798:sepantronium